Chart: FDA September 2005 Report of Medical Device Approvals
This article was originally published in The Gray Sheet
FDA September 2005 Report of Medical Device Approvals
You may also be interested in...
Abbott plans to focus its initial marketing of the Xact carotid stent on physicians most experienced with the device, which Abbott will launch immediately
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.